JPMorgan resumes BioCryst Pharma stock coverage with neutral rating

Investing.com•Mon, Jul 13, 2026, 08:06 AM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/analyst-ratings/jpmorgan-resumes-biocryst-pharma-stock-coverage-with-neutral-rating-93CH-4787589)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #jpmorgan #resumes #biocryst #pharma #stock #coverage #neutral #rating

More Headlines

FinanceInvesting.com• 8m ago

Why is Vodafone stock rallying today?

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 8m ago

Prudential placed on Positive Catalyst Watch at JPM on Hong Kong optimism

Developing story — details emerging. Check the source link for the latest updates.

FinanceMarketWatch• 8m ago

There’s good and bad news if you want to copy JPMorgan’s new AI agent that outperforms the 60/40 portfolio

JPMorgan says it’s designed an artificial-intelligent agent to evaluate markets and economic data and use it to outperform the standard 60/40 investing model, with less risk to boot.

FinanceInvesting.com• 9m ago

Gjensidige rises 3% as stronger margins offset Denmark legal hit

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 10m ago

Infleqtion: Disrupting Markets Via Quantum Sensing And Computing (Rating Upgrade)

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 10m ago

The SPCX IPO And Why The U.S. ETF Marketplace And Its Index Providers Will Never Be The Same

Developing story — details emerging. Check the source link for the latest updates.